Antibody Drug Conjugates Market Size, Share & Trends Analysis Report Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), By Technology (Cleavable, Non-cleavable), By Payload Technology, And Segment Forecasts, 2022 - 2030

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.11.3 Objective 2:
1.11.4 Objective 4
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Industry Outlook
3.1 Market Variable Analysis
3.2 Penetration and Growth Prospect Mapping
3.3 Driver Impact Analysis
3.3.1 Presence of strong product pipeline
3.3.2 Growing geriatric population base
3.3.3 Increasing incidence and prevalence of cancer
3.4 Market Restraint Analysis
3.4.1 High manufacturing cost and downstream processing challenges for ADCs
3.4.2 Analytical Challenges for ADc
3.4.3 Stringent Reimbursement policies for ADCs
3.5 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.6 Porter’s Five Forces Analysis
3.7 Qualitative Analysis for ADC Development Platforms
3.7.1 Creative Biolabs
3.7.2 Mersana Therapeutics
3.7.3 Heidelberg Pharma
3.7.4 Synaffix BV
3.7.5 NBE therapeutics
3.7.6 VERAXA
3.7.7 Tubulis GmbH
3.7.8 Byondis Platform
3.7.9 ImmunoGen, Inc.
3.7.10 RemeGen
3.7.11 WuXi Biologics
3.7.12 Merck KGaA
3.7.13 Ambrx
Chapter 4 APPLICATION BUSINESS ANALYSIS
4.1 Antibody Drug Conjugates Market: Application Movement Analysis
4.2 Blood Cancer
4.2.1 Blood Cancer market estimates and forecast, 2017 - 2030
4.2.2 Leukemia
4.2.2.1 Leukemia market estimates and forecast, 2017 - 2030
4.2.3 Multiple Myeloma
4.2.3.1 Multiple Myeloma market estimates and forecast, 2017 - 2030
4.2.4 Lymphoma
4.2.4.1 Lymphoma market estimates and forecast, 2017 - 2030
4.3 Breast Cancer
4.3.1 Breast Cancer market estimates and forecast, 2017 - 2030
4.4 Urothelial/Bladder Cancer
4.4.1 Urothelial Cancer market estimates and forecast, 2017 - 2030
4.5 Others
4.5.1 Others market estimates and forecast, 2017 - 2030
Chapter 5 TECHNOLOGY BUSINESS ANALYSIS
5.1 Antibody Drug Conjugates Market: Technology Movement Analysis
5.2 By Type
5.2.1 Cleavable Linker
5.2.1.1 Cleavable Linker market estimates and forecast, 2016-2028
5.2.2 Non-cleavable Linker
5.2.2.1 Non-cleavable Linker market estimates and forecast, 2016-2028
5.2.3 Linkerless
5.2.3.1 Linkerless market estimates and forecast, 2016-2028
5.3 By Linker Technology
5.3.1 VC
5.3.1.1 VC (valine-citrulline) market estimates and forecast, 2017 - 2030
5.3.2 Sulfo-SPDB
5.3.2.1 Sulfo-spdb market estimates and forecast, 2017 - 2030
5.3.3 VA (Valine Alanine)
5.3.3.1 VA (Valine alanine) market estimates and forecast, 2017 - 2030
5.3.4腙
5.3.4.1 Hydrazone market estimates and forecast, 2017 - 2030
5.3.5 Others
5.3.5.1 Others market estimates and forecast, 2017 - 2030
5.4 By Payload
5.4.1 MMAE
5.4.1.1 MMAE market estimates and forecast, 2017 - 2030
5.4.2 MMAF
5.4.2.1 MMAF market estimates and forecast, 2017 - 2030
5.4.3 DM4
5.4.3.1 DM4 market estimates and forecast, 2017 - 2030
5.4.4 Camptothecin
5.4.4.1喜树碱市场估计和预测, 2017 - 2030
5.4.5 Others
5.4.5.1 Others market estimates and forecast, 2017 - 2030
Chapter 6 Regional Business Analysis
6.1 Antibody Drug Conjugates Market: Regional Movement Analysis
6.2 NORTH AMERICA
6.2.1 North America Antibody drug conjugates market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Antibody drug conjugates market estimates and forecasts, 2017 - 2030 (USD Million)
6.2.3 CANADA
6.2.3.1 Canada Antibody drug conjugates market estimates and forecasts, 2017 - 2030 (USD Million)
6.3 EUROPE
6.3.1 EUROPE Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.2 UK
6.3.2.1 UK Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.3 GERMANY
6.3.3.1 Germany Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.4 ITALY
6.3.4.1 Italy Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.5 SPAIN
6.3.5.1 Spain Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.3.6 FRANCE
6.3.6.1 France Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 ASIA PACIFIC Antibody drug conjugates MARKET ESTIMATES AND FORECAST, 2017 - 2030 (USD Million)
6.4.2 JAPAN
6.4.2.1 Japan Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.3 CHINA
6.4.3.1 China Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.4 INDIA
6.4.4.1 India Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.5 AUSTRALIA
6.4.5.1 Australia Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5.2 BRAZIL
6.5.2.1 Brazil Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5.3 MEXICO
6.5.3.1 Mexico Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.5.4 ARGENTINA
6.5.4.1 Argentina Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6 Middle East & Africa
6.6.1 Middle East & Africa Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6.2 SOUTH AFRICA
6.6.2.1 South Africa Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6.3 SAUDI ARABIA
6.6.3.1 Saudi Arabia Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
6.6.4 UAE
6.6.4.1 UAE Antibody drug conjugates market estimates and forecast, 2017 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Major deals & strategic alliances analysis
7.1.1 New product launch
7.1.2 Mergers and acquisitions
7.1.3 Expansion
7.1.4 Partnerships
7.2 Vendor Landscape
7.2.1 List of key distributors and channel partners
7.3 Public Companies
7.3.1 Company market position analysis
7.3.2 Competitive Dashboard Analysis
7.4 Private Companies
7.4.1 List of key emerging companies/Technology disruptors/ innovators
Chapter 8 COMPANY PROFILES
8.1 Takeda Pharmaceutical Company Limited
8.1.1 Company overview
8.1.2 Financial Performance
8.1.3 Product benchmarking
8.1.4 Strategic initiatives
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company overview
8.2.2 Financial Performance
8.2.3 Product benchmarking
8.2.4 Strategic initiatives
8.3 Pfizer, Inc.
8.3.1 Company overview
8.3.2 Financial Performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 AstraZeneca
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 Gilead Sciences, Inc.
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Astellas Pharma Inc.
8.6.1 Company overview
8.6.2 Financial Performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 Seagen, Inc.
8.7.1 Company overview
8.7.2 Financial Performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 Daiichi Sankyo Company, Limited
8.8.1 Company overview
8.8.2 Financial Performance
8.8.3 Product benchmarking
8.8.4 Strategic initiatives
8.9 GlaxoSmithKline Plc.
8.9.1 Company overview
8.9.2 Financial Performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 ADC Therapeutics SA
8.10.1 Company overview
8.10.2 Financial Performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives
8.11 Synaffix BV
8.11.1 Company overview
8.11.2 Product benchmarking
8.11.3 Strategic initiatives

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 North America antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 4 North America antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 5 North America antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 7 North America antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 8 U.S. antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 9 U.S. antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 10 U.S. antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 11 U.S. antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 12 Canada antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 13 Canada antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 14 Canada antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 15 Canada antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 16 Europe antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 17 Europe antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 18 Europe antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 19 Europe antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 20 U.K. antibody drug conjugates market estimates and forecasts, by application, 2017 - 62028 (USD Million)
TABLE 21 UK antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 22 UK antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 23 UK antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 24 Germany antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 25 Germany antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 26 Germany antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 27 Germany antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
表28日法国抗体药物配合市场timates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 29 France antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 30 France antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 31 France antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 32 Italy antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 33 Italy antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 34 Italy antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 35 Italy antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 36 Spain antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 37 Spain antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 38 Spain antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 39 Spain antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 40 Russia antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 41 Russia antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 42 Russia antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 43 Russia antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 44 Asia Pacific antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 45 Asia Pacific antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 46 Asia Pacific antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 47 Asia Pacific antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 48 Japan antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 Japan antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 Japan antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 Japan antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 52 China antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 53 China antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 54 China antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 55 China antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 56 India antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 57 India antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 58 India antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 59 India antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 60 Australia antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 61 Australia antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 62 Australia antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 63 Australia antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 33 South Korea antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 South Korea antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 South Korea antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
表51韩国抗体药物配合et estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 35 Singapore antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 Singapore antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 Singapore antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 Singapore antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 37 Latin America antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 Latin America antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 Latin America antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 Latin America antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
表39巴西抗体药物配合市场timates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 Brazil antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 Brazil antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 Brazil antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 41 Mexico antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 Mexico antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 Mexico antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
表51墨西哥抗体药物配合市场timates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 43 Argentina antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
表49阿根廷抗体药物配合市场estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 Argentina antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 Argentina antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 44 MEA antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 MEA antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 MEA antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 MEA antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 46 South Africa antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 South Africa antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 South Africa antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 South Africa antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 48 Saudi Arabia antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 Saudi Arabia antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 Saudi Arabia antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 Saudi Arabia antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
TABLE 50 UAE antibody drug conjugates market estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 UAE antibody drug conjugates market estimates and forecasts, by technology type, 2017 - 2030 (USD Million)
TABLE 50 UAE antibody drug conjugates market estimates and forecasts, by linker technology, 2017 - 2030 (USD Million)
TABLE 51 UAE antibody drug conjugates market estimates and forecasts, by payload technology, 2017 - 2030 (USD Million)
Table 52 List of key distributors
Table 53 List of key emerging companies/technology disruptors/innovators

List of Figures

Fig. 1 Antibody drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Antibody drug conjugates market snapshot
Fig. 10 Antibody drug conjugates market driver impact
Fig. 11 Global population by age group, 2016, 2020, & 2027
Fig. 12 Global cancer cases projection,2020 - 2030 (Number of new registered cases)
Fig. 13 Antibody drug conjugates market restraint impact
Fig. 14 Penetration and growth prospect mapping
Fig. 15 SWOT analysis, by factor (political & legal economic and technological)
Fig. 16 Porter’s five forces analysis
Fig. 17 Antibody drug conjugates market: Application outlook and key takeaways
Fig. 18 Antibody drug conjugates market: Application movement analysis
Fig. 19 Blood cancer market estimates and forecasts, 2017 - 2030
Fig. 20 Leukemia market estimates and forecasts, 2017 - 2030
Fig. 21 Multiple Myeloma market estimates and forecasts, 2017 - 2030
Fig. 22 Lymphoma market estimates and forecasts, 2017 - 2030
Fig. 23 Breast cancer market estimates and forecasts, 2017 - 2030
Fig. 24 Urothelial cancer market estimates and forecasts, 2017 - 2030
Fig. 25 Others market estimates and forecasts, 2017 - 2030
Fig. 26 Antibody drug conjugates market: Technology outlook and key takeaways
Fig. 27 Antibody drug conjugates market: Technology movement analysis
Fig. 28 Cleavable linker market estimates and forecasts, 2017 - 2030
Fig. 29 Non-cleavable linker market estimates and forecasts, 2017 - 2030
Fig. 30 Linkerless market estimates and forecasts, 2017 - 2030
Fig. 31 VC (valine-citrulline) market estimates and forecasts, 2017 - 2030
Fig. 32 Sulfo-SPDB market estimates and forecasts, 2017 - 2030
Fig. 33 VA (valine alanine) market estimates and forecasts, 2017 - 2030
Fig. 34 Hydrazone market estimates and forecasts, 2017 - 2030
Fig. 35 Others market estimates and forecasts, 2017 - 2030
Fig. 36 MMAE market estimates and forecasts, 2017 - 2030
Fig. 37 MMAF market estimates and forecasts, 2017 - 2030
Fig. 38 DM4 market estimates and forecasts, 2017 - 2030
Fig. 39 Camptothecin market estimates and forecasts, 2017 - 2030
Fig. 40 Others market estimates and forecasts, 2017 - 2030
Fig. 41 Antibody drug conjugates market: Regional outlook and key takeaways
Fig. 42 Antibody drug conjugates market: Regional movement analysis
Fig. 43 North America
Fig. 44 North America market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 45 U.S.
Fig. 46 U.S. market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 47 Canada
Fig. 48 Canada market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 49 Europe
Fig. 50 Europe market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 51 UK
Fig. 52 UK market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 53 Germany
Fig. 54 Germany market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 55 Italy
Fig. 56 Italy market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 57 Spain
Fig. 58 Spain market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 59 Russia
Fig. 60 Russia market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 61 France
Fig. 62 France market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 63 Asia Pacific
Fig. 64 Asia Pacific market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 65 Japan
Fig. 66 Japan market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 67 China
Fig. 68 China market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 69 India
Fig. 70 India market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 71 Australia
Fig. 72 Australia market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 73 South Korea
Fig. 74 South Korea market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 75 Singapore
Fig. 76 Singapore market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 77 Latin America
Fig. 78 Latin America market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 79 Brazil
Fig. 80 Brazil market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 81 Mexico
Fig. 82 Mexico market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 83 Argentina
Fig. 84 Argentina market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 85 Middle East & Africa
Fig. 86 Middle East and Africa market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 87 South Africa
Fig. 88 South Africa market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 89 Saudi Arabia
Fig. 90 Saudi Arabia market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 91 UAE
Fig. 92 UAE market estimates and forecast, 2017 - 2030 (USD Million)
Fig. 93 Company market share analysis
Fig. 94 Company market position analysis (Revenue US$ mn)
Fig. 95 Company market position analysis (Profit Margin)
Fig. 96 Competitive dashboard analysis
Fig. 97 Regional Network Map